×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Articles

Debi Boyle MSN, RN, AOCNS, FAAN
I poignantly remember an eloquent wife of a patient who died of acute leukemia shared her analogy with me. She stated, “You know when my dog died, I got a card from my vet. When my husband died, I got nothing.”
Brielle Urciuoli
Previously, there were concerns that older patients would not be able to handle the toxicities of the procedure, or that their stem cells, which are older, would not work as well. But that proved to not be the case.
Tracy Posner
Life after a hysterectomy is one of the many challenges I have had to overcome.
Kristie L. Kahl
A small study showed that, despite national guideline recommendation, conversations between doctors and patients about the benefits and harms of lung cancer screening in those who are at high risk are not happening the way they should be.
CURE Media Group, the nation’s leading digital and print media enterprise dedicated to patients and survivors of cancer, will launch its first television commercial featuring curetoday.com during the Stand Up To Cancer (SU2C) telecast tonight.
Terry Lynn Arnold
Patti Kellerhouse
This is my survivor story and how my dragon boat involvement continues to help me get through my breast cancer journey.
Brielle Urciuoli
After success in the non-small cell lung cancer space, immunotherapy is finally making waves in the treatment of small cell lung cancer.
Brielle Urciuoli
This infographic explains some of the basics on mantle cell lymphoma, a type of non-Hodgkin lymphoma.
Silas Inman
The FDA has granted LOXO-292 a breakthrough therapy designation for the treatment of patients with RET fusion–positive non–small cell lung cancer (NSCLC) or RET-mutant medullary thyroid cancer (MTC). This designation will expedite the development and review of the drug.
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×

Sign Up

In Treatment

Maintenance/Hormone Treatment

Out of Treatment

Caregiver

Healthcare Professional

Not Applicable